Vyome Showcases Transformative Phase 2 Clinical Results for VT-1953 at AACR 2026
Vyome Holdings, Inc. (Nasdaq: HIND), a clinical-stage biotechnology company focused on developing innovative therapies for underserved conditions, has unveiled comprehensive Phase 2 investigator-initiated study results along with supporting preclinical data for its lead candidate VT-1953. The findings were presented at the American Association for Cancer Research Annual Meeting 2026, held in San Diego on April 21, 2026, highlighting the therapy’s potential as a first-in-class treatment for symptoms associated with malignant fungating wounds (MFW).
Malignant fungating wounds are a severe and often overlooked complication in patients with advanced cancers. These wounds, which affect approximately 10% of individuals with late-stage malignancies—equating to around 65,000 patients annually in the United States—are characterized by chronic, non-healing lesions that can cause distressing symptoms. Among the most debilitating are intense malodor, often described as resembling “rotting flesh,” and persistent pain. These symptoms frequently lead to profound psychological and social consequences, including embarrassment, isolation, and a diminished quality of life. Despite the significant burden, there are currently no therapies approved by the U.S. Food and Drug Administration specifically to address these symptoms.
VT-1953, Vyome’s investigational topical therapy, is being developed to directly target the underlying causes of these distressing symptoms. The drug is designed with a dual mechanism of action: it inhibits bacterial DNA gyrase, which plays a role in microbial proliferation, and modulates MD2/TLR signaling pathways involved in inflammation. This combined approach aims to both reduce odor-causing bacterial activity and alleviate inflammatory processes contributing to wound-related discomfort.
The Phase 2 study evaluated VT-1953 in patients with advanced cancer suffering from MFW. At baseline, patients exhibited extremely severe malodor, with a median score of 0.5 on the TELER scale—a clinically validated measurement tool ranging from 0 to 5, where lower scores indicate worse odor. A score of 0.5 corresponds to an odor detectable from a distance of 6 to 10 feet even when the wound is covered with a dressing.
Following treatment with VT-1953, patients demonstrated a marked and statistically significant improvement in malodor. By Day 14, the median score improved to 4, indicating only mild odor detectable at close proximity and typically only after removal of the dressing. This improvement was highly significant (P=0.0020) and met the study’s primary endpoint. In contrast, patients in the control group receiving the vehicle (placebo gel) showed no meaningful change, with median scores remaining unchanged from baseline to Day 14 (P=0.9999). The difference between the treatment and control groups was also statistically significant (P=0.0015), underscoring the therapeutic effect of VT-1953.
Secondary endpoints further reinforced the clinical benefit of VT-1953. Patients were asked to evaluate how malodor affected their daily lives, using a scoring system where higher scores indicated less impact. Among those treated with VT-1953, 70% reported a meaningful improvement, achieving scores between 3 and 5 by Day 14, compared to a baseline score of 0. In stark contrast, none of the patients in the control group reported improvement (P=0.0256). These findings highlight the therapy’s potential not only to reduce physical symptoms but also to improve patients’ emotional well-being and social functioning.
Additional patient-reported outcomes were assessed using a 10-point visual analog scale (VAS) for odor severity, where 0 represents no odor and 10 represents the worst possible odor. Patients receiving VT-1953 experienced a significant reduction in median odor scores, from 7.5 at baseline to 2.5 by Day 14 (P=0.0020). Conversely, patients in the control arm reported a worsening of symptoms, with median scores increasing from 6.0 to 7.0 over the same period.
Pain, another critical symptom associated with MFW, was also evaluated using the VAS scale. Patients treated with VT-1953 reported a clinically meaningful reduction in pain, with a two-point improvement by Day 14 (P=0.0020). No such improvement was observed in the control group. Notably, while VT-1953 demonstrated clear benefits in reducing malodor and pain, it did not significantly alter levels of wound exudate, indicating a targeted effect on specific symptom domains.
Equally important, the treatment exhibited a strong safety profile. No treatment-related adverse events were reported במהלך the study, suggesting that VT-1953 may offer a well-tolerated option for patients who are often already burdened by intensive cancer therapies and compromised health.
Commenting on the results, Dr. Shiladitya Sengupta, co-founder of Vyome and associate professor of medicine at Harvard Medical School, emphasized the broader impact of the findings. He noted that the ability to alleviate malodor and pain could significantly improve patients’ quality of life, enabling them to maintain closer social connections and avoid the isolation often associated with this condition.
Vyome’s Chief Executive Officer, Venkat Nelabhotla, also highlighted the significance of the data, pointing to the strong statistical outcomes that exceeded conventional thresholds for significance. He indicated that these results provide confidence as the company moves toward designing registrational studies, potentially with smaller patient populations due to the robustness of the observed effects.
Beyond clinical implications, the company also underscored the commercial potential of VT-1953. Independent third-party analyses estimate that the total addressable market for MFW treatments in the United States could reach approximately $2.2 billion. Given the absence of approved therapies and the significant unmet medical need, VT-1953 has the potential to become a transformative option in this niche but impactful therapeutic area.
The presentation of these results at a major scientific forum like the American Association for Cancer Research Annual Meeting further validates the growing interest in supportive oncology care, particularly in addressing symptoms that profoundly affect patient dignity and quality of life. As Vyome advances VT-1953 into the next phase of development, the therapy may represent a meaningful step forward in improving care for patients living with advanced cancer and its most challenging complications.
About Vyome Holdings, Inc.
Based in Cambridge, MA, Vyome’s immediate focus is on leveraging its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions. By applying groundbreaking science and its unique positioning across the US-India innovation corridor, Vyome seeks to deliver lasting value to shareholders in a hyper cost-efficient manner while upholding global standards of quality and safety.
Source Link:https://www.businesswire.com/
